<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/app/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.4"?>
<!-- generated-on="2026-06-05T08:53:58+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.4" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.pharma-marketing.com/bayer-ceo-bill-anderson-warns-of-germanys-competitiveness-gap/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-05T06:59:48+00:00</news:publication_date><news:title>Bayer CEO Bill Anderson warns of Germany’s competitiveness gap</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/bayer-ceo-bill-anderson-sieht-deutschland-im-standortnachteil/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-05T06:59:48+00:00</news:publication_date><news:title>Bayer-CEO Bill Anderson sieht Deutschland im Standortnachteil</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/boehringer-ingelheim-halts-planned-investment-in-germany/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-05T06:55:23+00:00</news:publication_date><news:title>Boehringer Ingelheim halts planned investment in Germany</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/boehringer-ingelheim-stoppt-investitionen-in-deutschland/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-05T06:55:22+00:00</news:publication_date><news:title>Boehringer Ingelheim stoppt Investitionen in Deutschland</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/patient-first-disease-language-gains-momentum-in-pharma/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-05T06:50:42+00:00</news:publication_date><news:title>Patient-first disease language gains momentum in pharma</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/patientenorientierte-sprache-warum-krankheitsbegriffe-sich-aendern/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-05T06:50:42+00:00</news:publication_date><news:title>Patientenorientierte Sprache: Warum Krankheitsbegriffe sich ändern</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/sanofi-picks-snowflake-to-scale-ai-across-drug-development/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-05T06:46:36+00:00</news:publication_date><news:title>Sanofi picks Snowflake to scale AI across drug development</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/sanofi-setzt-bei-ki-gestuetzter-entwicklung-auf-snowflake/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-05T06:46:36+00:00</news:publication_date><news:title>Sanofi setzt bei KI-gestützter Entwicklung auf Snowflake</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/italy-probes-biogen-over-tysabri-test-and-market-abuse-claims/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-03T10:46:21+00:00</news:publication_date><news:title>Italy probes Biogen over Tysabri test and market abuse claims</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/italiens-wettbewerbshueter-pruefen-biogen-wegen-tysabri-test/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-03T10:46:21+00:00</news:publication_date><news:title>Italiens Wettbewerbshüter prüfen Biogen wegen Tysabri-Test</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/lars-rose-nominated-as-next-mvfp-chair/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-06-03T10:20:00+00:00</news:publication_date><news:title>Lars Rose nominated as next MVFP chair</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/lars-rose-soll-neuer-mvfp-vorsitzender-werden/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-06-03T10:19:59+00:00</news:publication_date><news:title>Lars Rose soll neuer MVFP-Vorsitzender werden</news:title></news:news></url>
</urlset>
